Madrigal Pharmaceuticals Secures Three New Resmetirom U.S. Patents
CONSHOHOCKEN, Pa., July 13, 2026 Madrigal Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued three...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
CONSHOHOCKEN, Pa., July 13, 2026 Madrigal Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued three...
Lille, France; Cambridge, Massachusetts, United States; and Zurich, Switzerland, July 2, 2026 GENFIT announced that U.S. Medicare has approved...
Princeton, New Jersey, November 10, 2025 — PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company developing next-generation immunotherapies for cancer...
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., November 7, 2025 — Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pioneering...
